FAM
NRIX icon

Fred Alger Management’s Nurix Therapeutics NRIX Stock Holding History

Fred Alger Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-168,762
Closed -$3.18M – 461
2024
Q4 		$3.18M Buy
168,762
+2,748
+2% +$63K 0.02% 288
2024
Q3 		$3.73M Buy
166,014
+127,948
+336% +$2.9M 0.02% 273
2024
Q2 		$794K Buy
+38,066
New +$593K ﹤0.01% 363
2022
Q3 		– Sell
-7,306
Closed -$93K – 550
2022
Q2 		$93K Buy
+7,306
New +$82.8K ﹤0.01% 440

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fred Alger Management's NRIX Position: Q1 2025 in Review

Fred Alger Management sold out of Nurix Therapeutics (NRIX) in Q1 2025, closing a stake of 168,762 shares — an estimated $3.18M sold.

Fred Alger Management first reported a position in NRIX in Q2 2022 and held it in 4 quarters. The position peaked at $3.73M in Q3 2024. 170 funds tracked by Wall St. Rank hold NRIX as of Q1 2025.

  • Fred Alger Management reported no remaining Nurix Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Fred Alger Management sold 168,762 Nurix Therapeutics shares in Q1 2025, an estimated $3.18M.
  • Fred Alger Management first reported a position in Nurix Therapeutics in Q2 2022 and held it in 4 quarters.
  • Fred Alger Management's Nurix Therapeutics position peaked at $3.73M in Q3 2024.
  • 170 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2025.

Based on Fred Alger Management's 13F filing for Q1 2025, filed 16 May 2025.